Acrux (ASX:ACR) share price comes crashing back to earth on patent challenge


The Acrux Limited (ASX:ACR) share price has crashed 6 cents or 21.8 per cent lower to 21.5 cents after the emerging pharmaceutical company said Valeant Pharmaceuticals initiated patent litigation against Acrux regarding its generic Jublia Topical Solution, 10%.

In a statement to the ASX, Acrux said the action by Valeant is expected and formerly initiates the litigation process.

Last week, Acrux shares went ballistic after a presentation by the company said the Acrux Board viewed its topical generic portfolio as being undervalued by the market, especially given the company’s $28.5 million cash balance.

Acrux’s Jublia Topical Solution product is the most advanced of its generics. The company is seeking a licensing agreement with a large generic company who will market and sell the product in the US.

The timing of the product launch is dependent on FDA approval and the legal outcome of the patent litigation. Acrux shares are falling because of the uncertainty of the outcome of the patent challenge and the potential delay in product launch.

After the fall in the Acrux share price, the company has am enterprise value of just $18 million. Management previously said it reasonably expects there to be sufficient funding to progress the current product pipeline through to launch.

Acrux shares don’t look cheap, but these 3 shares do…

Combining countless hours of research with over 30 years of hands-on stock market investing experience, The Capital Club’s founder Bruce Jackson has just published his definitive list of 3 Cheap and Good ASX Stocks for 2018.

Acrux was not one of them, but the list does include one tiny gold mining stock, and the company one top fund manager calls the cheapest stock in the ASX 100.

Find out why these 3 Cheap and Good Stocks could be better buys than Acrux. But you better hurry… these stocks may not stay cheap for long.

See the 3 stocks

Contributors to this article may own shares in some of the companies mentioned in this article. The Capital Club has a thorough disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Bruce Jackson.
Bruce Jackson has 30 years of hands on investing experience. He is passionate about stock market investing, running his own portfolio and SMSF. His focus is on small cap growth stocks. You can contact Bruce at